1. Home
  2. NIE vs GOSS Comparison

NIE vs GOSS Comparison

Compare NIE & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Equity & Convertible Income Fund of Beneficial Interest

NIE

Virtus Equity & Convertible Income Fund of Beneficial Interest

HOLD

Current Price

$25.56

Market Cap

704.1M

Sector

Finance

ML Signal

HOLD

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.40

Market Cap

615.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NIE
GOSS
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
704.1M
615.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NIE
GOSS
Price
$25.56
$0.40
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$5.90
AVG Volume (30 Days)
46.3K
21.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
9.04%
N/A
EPS Growth
N/A
78.81
EPS
N/A
N/A
Revenue
N/A
$114,701,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.54
$0.33
52 Week High
$26.00
$3.87

Technical Indicators

Market Signals
Indicator
NIE
GOSS
Relative Strength Index (RSI) 53.86 14.80
Support Level $24.71 N/A
Resistance Level $25.62 $1.31
Average True Range (ATR) 0.32 0.15
MACD 0.02 -0.21
Stochastic Oscillator 76.00 3.37

Price Performance

Historical Comparison
NIE
GOSS

About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest

Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Share on Social Networks: